Emerging Therapies for Nonalcoholic Fatty Liver Disease

Area of Science:

• Hepatology
• Gastroenterology
• Pharmacology

Background:

• Nonalcoholic fatty liver disease is the leading cause of chronic liver disease in the U.S.
• Nonalcoholic steatohepatitis (NASH) currently has no FDA-approved pharmacologic treatments.
• The complex pathogenesis of NASH involves multiple molecular pathways.

Purpose of the Study:

• To review the current landscape of therapeutic targets and agents in development for NASH.
• To highlight the need for long-term clinical data for drug approval.

Main Methods:

• Review of current scientific literature and ongoing clinical trials.
• Analysis of the multifactorial nature of NASH pathogenesis.
• Discussion of regulatory requirements for NASH therapeutics.

Main Results:

• Multiple therapeutic targets are being investigated for NASH.
• Several promising agents are in various phases of clinical trials.
• No single pathway may be sufficient for effective treatment.

Conclusions:

• Targeting multiple pathways may be necessary for effective NASH treatment.
• Long-term clinical benefit and safety data are essential for the approval of new NASH therapies.
• The development of effective NASH treatments is an active area of research.